Study On Treating Intermediate Stage And Advanced Primary Live Cancer (PLC) With Single TCM

Background: Primary liver cancer is malignant tumor which origin from hepatocyte or epithelial cells of bile duct. lt is highly malignant, rarely diagnosed during the early stage, prognosis is bad. It is reportedthat PLC's mortality rate is44/100, 000 by the Ministry of Public Health in 1995, taking the second place among all of the malignant tumors. As in early stage, operation is still considered the best treatment. However, when was found, the majority of the patients of PLC are already in mid stage or even advanced disease, or complicated by Cirrhosis of liver, so miss their opportunities of resection. interventional therapy and other local therapy, such as TACE,PEI,RFA, always can not be done due to the great mass or poor liver function. TCM treatment with Syndrome Differentiation and Disease Differentiation, has both effections of strengthening body resistance and anticancer, is becoming one important alternative to treat PLC, it is widespread in China, but There are rare good clinic trials to estimate and to show the contribution of anticancer for TCM, especially with single TCM method.Objective: Abserve and evaluate the therapeutic effectiveness for PLC by the therapy of single TCM, to find an effective alternative to fight agginst PLC, expect a long survival rate,improving Quality-of-life(QOL) for PLC patients.Methods: Collect cases fit our standard in Guangdong Province Hospital of TCM from August 1st 1997 to December 1st 2006, divide into two teamS, one team have accepted the TACE in-patient clinic(34 cases); the other was given Chinese Madicine orally with Syndrome Differentiation or diease Differentiation(31 cases). Record mass variety by CT,MRI or BUS, symptoms, Karnofsky performance status(KPS), the childs grade of liver function, serum level of AFP,GGT,TBIL, QOL,(every 3 months). Using the software of SPSS13.0, to statistic the index above,Median survival times(MST), and the survival rate etc, to analyze the outcome according to clinical circumstances. Result:â‘ The tumour mark AFP before or after therapy was tested by T test, in the TCM team P value is 0.217, no statistical difference; in the TACE team P value is 0.035, has statistical difference, it means the level of serum AFP decreased significantly after TACE.â‘¡Average Survival time, median survival time is 15.58m and 9.00m in ICM team, is 14.35m and 7.50m in IACE team, TCM team is a litter longer than TACE team, but there is no statistical difference(P=0.272). compare the survival rate in two teams at the time points of 12m,18m,2y, no statistical difference. When the observation time was over in March 2007, there is 14 survivals in TCM team and 5 survivals in TACE team.â‘¢To analyze the predictors of survival time by linear Regression, the outcome is same in different teams, the times of TACE is protective factor, others PS,Child-pugh score,stage are negative factors.Conclusion: The research show that: Compare with TACE team, the TCM team has similar or better effects on improving PS,Karnofsky performance status(KPS), TACE team has a longer survival time, but no statistical difference. TACE team has a better effect on decreasing the level of serum AFP. Single therapy of TCM is a effective, practical treatment for intermediate stage and advanced Primary Live Cancer(PLC).